Morgan Stanley Idera Pharmaceuticals, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.23 - $0.43 $3,207 - $5,996	13,946 Added 15.24%	105,483 $36,000
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.53 $2,886 - $4,025	7,596 Added 9.05%	91,537 $34,000
Q2 2022 Oct 27, 2022	SELL	$0.32 - $0.74 $13,801 - $31,916	-43,130 Reduced 33.94%	83,941 $39,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.74 $13,801 - $31,916	-43,130 Reduced 33.94%	83,941 $39,000
Q1 2022 Oct 27, 2022	BUY	$0.41 - $0.7 $17,683 - $30,190	43,130 Added 51.38%	127,071 $64,000

Q1 2022 May 13, 2022	BUY	$0.41 - $0.7 $365 - $624	892 Added 0.71%	127,071 $64,000
Q4 2021 Feb 14, 2022	SELL	$0.53 - $1.03 $2,175 - $4,227	-4,104 Reduced 3.15%	126,179 $72,000
Q3 2021 Nov 15, 2021	BUY	$1.0 - $1.18 $130,283 - $153,733	130,283 New	130,283 $133,000

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.